5R01AG061100-04 |
2021 |
$2324251 |
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD) |
5R01AG061100-03 |
2020 |
$2344010 |
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD) |
5R01AG061100-02 |
2019 |
$2341700 |
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD) |
1R01AG061100-01 |
2018 |
$2415140 |
A RANDOMIZED CONTROLLED TRIAL OF ELECTROCONVULSIVE THERAPY PLUS USUAL CARE VERSUS SIMULATED-ECT PLUS USUAL CARE FOR THE ACUTE MANAGEMENT OF SEVERE AGITATION IN ALZHEIMER'S DEMENTIA (ECT-AD) |